Abstract
In a double blind placebo-controlled study rotavirus vaccine RIT 4237 was offered to young infants after the fourth week of life. The vaccine was very well tolerated. Fifty-seven out of 100 vaccine recipients and 10 out of 103 placebo recipients developed rotavirus-IgM-antibodies during the 1 month follow-up period. During a 6 month follow-up, stool samples from 2 out of 12 vaccinees and from 5 out of 12 placebo recipients contained rotavirus.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bishop RF, Davidson GP, Holmes IH (1973) Virus particles in epithelial cells of duodenal mucosa from children with acute non-bacterial gastroenteritis. Lancet II:1281
Delem A, Vesikari T (1987) Detection of serum antibody responses to RIT 4237 rotavirus vaccine by ELISA and neutralization assays. J Med Virol 21:231–238
Dominick HC, Maass G (1979) Rotavirusinfektionen im Kindesalter. Klin Padiatr 191:33–39
Edelman R (1987) Perspective on the development and deployment of rotavirus vaccines. Pediatr Infect J 6:704–710
Flores J, Perez-Schael I, Gonzales M, Garcia D, Perez M, Daoud N, Cunto W, Chanock RM, Kapikian AZ (1987) Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in venezuelan infants. Lancet I:882–884
Maldonado Y, Hestvik L, Wilson M, Townsend T, O'Hare J, Wee S, Yolken R (1986) Safety and immunogenicity of bovine rotavirus vaccine RIT 4237 in 3-month-old infants. J Pediatr 109:931–935
Rennels MB, Losonsky GA, Levine MM, Kapikian AZ (1986) Preliminary evaluation of the efficacy of rhesus rotavirus vaccine strain MMU 18006 in young children. Pediatr Infect Dis J: 5:587–588
Rennels MB, Losoncky GA, Shindledecker CL, Hughes TP, Kapikian AZ, Levine MM (1987) Immunogenicity and reactogenicity of lowered doses of rhesus rotavirus vaccine strain MMU 18006 in young children. Pediatr Infect Dis J:6:260–264
Vesikari T, Isolauri E, Delem A, D'Hondt E, Andrè FE (1983) Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children. Lancet II:807–811
Vesikari T, Isolauri E, D'Hondt E, Delem A, Andrè FE, Zissis G (1984) Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet I:977–981
Vesikari T, Isolauri E, D'Hondt E, Delem A, Andrè FE (1984) Increased “take” rate of oral rotavirus vaccine in infants after milk feeding. Lancet II:700
Vesikari T, Isolauri E, Delem A, D'hondt E, Andrè FE, Beards GM, Flewett TH (1985) Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J Pediatr 107:189–194
Vesikari T, Ruuska T, Bogaerts H, Delem A, Andrè FE (1985) Dose-response study of RIT 4237 oral rotavirus vaccine in breastfed and formula-fed infants. Pediatr Infect Dis 4:622–625
Vesikari T, Kapikian AZ, Delem A, Zissis G (1986) A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J Infect Dis 153:832–839
Vesikari T, Ruuska T, Delem A, Andrè FE (1987) Neonatal rotavirus vaccination with RIT 4237 bovine rotavirus vaccine: a preliminary report. Pediatr Infect Dis J 6:164–169
Zoppi G, Ferrarini G, Rigolin F, Bogaerts H, Andrè FE (1986) Ansprechen auf den oralen Rotavirus-Impfstoff RIT 4237 bei Brust- und Flaschenkindern. Helv Paediatr Acta 41:203–208
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mutz, I.D., Krainer, F., Deutsch, J. et al. A trial of RIT-4237 rotavirus vaccine in 1-month-old infants. Eur J Pediatr 148, 634–635 (1989). https://doi.org/10.1007/BF00441518
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00441518